Clinical Stem Cell Manufacturing

Sponsored by: The Cell Culture Dish
Session ends: Closed
Answers by: Ronnda Bartel, Ph.D., Chief Scientific Officer, Aastrom Biosciences.

Session TopicAsk the Expert

There are an increasing number of promising new stem cell therapy candidates in development and many are showing promising results in clinical studies. As more stem cell therapies move from the lab to the clinical setting, there is increased interest in identifying best practices for stem cell manufacturing. Many researchers have specific questions about scaling up stem cell production, optimizing culture media, selecting the right manufacturing equipment, and the regulatory requirements for clinical production. If you have questions regarding stem cell manufacturing, then please join us for a special Ask the Expert session “Clinical Stem Cell Manufacturing.”


Questions & Answers

In my past I spent a great deal of time scaling up primary muscle and neuronal cell lines for gene expression studies. This requires some specialized techniques, and often some creativity, to maintain them in an undifferentiated state and to differentiate them on command. Coaxing primary lines to maintain the capability to differentiate over many passages was a challenge. I find myself wondering if the challenges seen with stem cells today, especially in scale up are similar to those that were present in growing differentiative cell lines more than 20 years ago. Do you feel that, as an industry, we are combining the lessons learned from work with differentiative cultures and large scale up of mammalian cell lines effectively?

I think the challenges you describe are definitely still there but do think significant progress has been made in the industry to address them. Cell therapies have been around for more than 20 years despite only a few being approved by the FDA and other regulatory agencies. Many lessons have been learned, especially through the […]» Read More

What do you think is the importance of having serum free and/or animal free media in clinical stem cell manufacturing?

Animal-free, chemically defined media would be the ideal choice for all stem cell manufacturing from the standpoint of consistency and control of materials. However, not all cells can be expanded and/or differentiated without serum or other animal derived materials. The use of animal derived materials is acceptable with the appropriate sourcing of materials and testing […]» Read More

Can you explain the difference between autologous and allogeneic stem cell therapies in terms of how they are manufactured clinically.

All stem cell therapies should be manufactured under Good Manufacturing Practices (GMPs). The primary difference between allogeneic and autologous are the source of the cells for the therapy. Allogeneic therapies are manufactured in large batches from unrelated donor tissues (such as bone marrow) whereas autologous therapies are manufactured as a single lot from the patient […]» Read More

Hello, I am Brazilian and pharmacist, and I would like to know in which areas and or services with stem cells, a pharmacist is able to act, and what specializations are suggested to my occupation for that purpose (stem cells).

The role of the pharmacist in the administration of stem cell therapies has yet to evolve, in my opinion. Currently, pharmacists are being utilized in stem cell clinical trials in two ways; 1) to dispense cellular therapies (from a bag to syringes, for example) to maintain the blinding of the physician administering the therapy and […]» Read More